Venture Capital

Major outages are often caused by simple network config errors, not data loss. A new approach to disaster recovery targets this overlooked vulnerability.

Struggling biotech Jupiter Neurosciences presents its Parkinson's drug to elite investors at Mar-a-Lago, betting its hybrid business model can win funding.

Amid a volatile market, Rock Tech Lithium's latest funding from existing investors signals strong confidence in its strategy to build a local battery supply chain.

Amid growing parts shortages, SurplusGLOBAL's upgraded SemiMarket uses AI and a circular 'Harvest' model to keep aging but essential semiconductor lines running.

With $280M in new funding, Beijing's Spirit AI is using real-world 'dirty data' to build a universal robot brain, challenging Google and Tesla.

A new partnership tackles AI's hidden bottleneck, using advanced interconnects to boost AMD-powered cloud performance, reliability, and efficiency.

Destination marketing leader Digital Edge is now Go Fish Tourism + Business Events, integrating AI and expanded services to unify leisure and business travel promotion.

After a mixed earnings report, ScanSource's CFO will outline the firm's pivot to recurring revenue and converging tech at a key investor conference.

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

A new Dubai-based VC firm is launching with a radical model: providing startups with a 24/7 AI workforce to slash costs and accelerate growth.

Rise Wellness launches its new 30g carbonated protein drink at Costco, betting on fizz and function to capture a rapidly growing, competitive market.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

With an $11.75M boost, a new device promises blood results in minutes, not hours, signaling a major pharma player's strategic pivot into diagnostics.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

A new partnership between Salience Labs and Tower Semiconductor aims to mass-produce optical switches, a critical technology for faster, greener AI data centers.

As global ESG rules become a complex web, Datamaran's new AI platform aims to help firms move from reactive compliance to proactive corporate strategy.

With a new CEO at the helm and a pivotal trial for its lead drug on the horizon, all eyes are on PureTech's upcoming investor conference presentation.